Introducing ZAVICEFTA: A combination of ceftazidime and avibactam1

Avibactam is a novel β-lactamase inhibitor combined with
ceftazidime, a cephalosporin with established clinical experience2

ceft_avibact_shield-01

Avibactam is:

  • A reversible, non-β-lactam β-lactamase inhibitor3
  • A covalent, slowly reversible inhibitor – a unique mechanism of
    inhibition among β-lactamase inhibitors3

Structure of avibactam3

stucture_avibactam

ZAVICEFTA: Potent inhibitory activity against difficult-to-treat
infections due to aerobic Gram-negative bacteria1,2

Avibactam inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including:1*

  • ESBLs
  • KPCs
  • OXA-48 carbaenemases
  • AmpC enzymes

lactamases

ZAVICEFTA is effective against infections with Enterbacteriaceae and P. aeruginosa with EUCAST minimum inhibitory concentrations as follows:1

susceptibel_resistant_organism

*Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many class D enzymes.1

ZAVICEFTA: A novel combination of ceftazidime and avibactam1

For the treatment of patients with suspected or documented Enterobacteriaceae and P. aeruginosa infection with resistance including to ESBLs, KPC & OXA-48 carbapenemases and AmpC enzymes.

Ceftazidime: Third-generation antipseudomonal cephalosporin4

• Inhibits bacterial peptidoglycan cell wall synthesis following binding to penicillin binding proteins (PBPs), which leads to bacterial cell lysis and death1

Avibactam: The first non-β-lactam, β-lactamase inhibitor3,5

 • A non β-lactam, β-lactamase inhibitor that acts by forming a covalent adduct with the enzyme that is stable to hydrolysis5

• Unlike traditional β-lactamase inhibitors, which may be hydrolysed to an inactive form, avibactam remains intact and active after release from the enzyme6,7

• This combination inhibits both Ambler Class A and Class C β-lactamases and some Class D enzymes, including extended-spectrum β-lactamases (ESBLs), KPC and OXA-48 carbapenemases, and AmpC enzymes1

• Avibactam does not inhibit Class B enzymes (metallo-β-lactamases) and is not able to inhibit many Class D enzymes1

Abbreviations:
cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; ESBL, extended-spectrum β-lactamase; EUCAST, European Committee on Antimicrobial Susceptibility Testing, HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; VAP, ventilator-associated pneumonia.

References:

  1. ZAVICEFTA. Summary of Product Characteristics.
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.
  3. Ehmann DE, et al. PNAS 2012;109:11663–8.
  4. Ceftazidime. Summary of product characteristics.
  5. Bush K. Int J Antimicrob Agents 2015;46:483–93.
  6. Ehmann DE, et al. J Biol Chem 2013;288:27960–71.
  7. Lahiri SD, et al. Antimicrob Agents Chemother 2013:57:2496–505
Prescribing Information
Meronem IV 1g – SPC 
Legal Category: POM.       Basic NHS Cost: 10 vial pack £206.28
Meronem IV 500mg – SPC 
Legal Category: POM.       Basic NHS Cost: 10 vial pack £103.14

 

Piperacillin/tazobactam
Tazocin 2 g/0.25 g Powder for Solution for Infusion – SPC
Legal category: POM.       Basic NHS cost: 1 vial pack £7.65 
Tazocin 4  g/0.5 g Powder for Solution for Infusion – SPC
Legal category: POM.       Basic NHS cost: 1 vial pack £15.17 
 
Tygacil 50 mg Powder for Solution for Infusion – SPC
Legal Category: POM.       Basic NHS Cost: 10 vial pack £323.10
 
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM.       Basic NHS price: 10 vial pack £857.00.

PP-ZVA-GBR-0628.  October 2019